Management of Prolonged aPTT with Normal PT

Initial Diagnostic Approach

The American College of Cardiology recommends verifying current anticoagulant therapy, particularly unfractionated heparin (UFH), low molecular weight heparin (LMWH), or direct thrombin inhibitors, as these are the most common causes of isolated aPTT prolongation 1, 2
A comprehensive review of medication history is necessary, as multiple drugs can affect aPTT beyond anticoagulants 1
Assessing for bleeding or thrombotic history is crucial to guide the urgency and direction of the workup 1

For patients on UFH therapy, the target aPTT range is 1.5-2.5 times the control value for therapeutic anticoagulation 1, 2
The American Heart Association suggests considering monitoring with anti-Xa levels (target 0.3-0.7 IU/mL) instead of aPTT when the baseline aPTT is prolonged 1, 2
Standard IV dosing is 80 U/kg bolus followed by 18 U/kg/hour infusion, adjusted to maintain the target aPTT 2
For heparin reversal in bleeding, administer protamine sulfate 1 mg per 100 units of heparin given in the last 2-3 hours (maximum 50 mg) via slow IV infusion 1, 2

For mild deficiencies (5-40% factor activity), hold immune checkpoint inhibitors if applicable and discuss resumption after risk-benefit assessment 3, 4
Administer prednisone 0.5-1 mg/kg/day for immune-mediated deficiencies 3, 4
Provide transfusion support as required for bleeding episodes 3, 4

Maintain platelets >50,000/μL, fibrinogen >150 mg/dL, and normalize PT/aPTT in patients with clinical coagulopathy and evident bleeding 1
Avoid routine correction with fresh frozen plasma in patients without active bleeding 1
Use UFH with careful monitoring instead of LMWH when creatinine clearance <30 mL/min due to drug accumulation risk 1, 2
Heparin does not cross the placenta and is safer than warfarin during pregnancy 2
LMWH may offer advantages over UFH in pregnant patients 2